One company has become Wall Street's money tree

Money tree

Pharmaceutical giant Teva agreed to buy Allergan’s generic drug arm for about $US40.5 billion on Monday.

That should cement the Israel-based company’s position as the top generic drugmaker in the world.

It will also be great for Wall Street banks, which will reap millions in advisory and other fees.

Irish-based Actavis last year bought Allergan for $US66 billion, and kept the name.

Together, those two firms have generated some $US780 million in investment banking fees for mergers and acquisition advice and equity, debt and loan deals since 2012, according to consultant Freeman & Co.

Now, the Teva deal should boost total Allergan-Actavis fees to about $US820 million, according to Freeman, with Allergan adviser JPMorgan in line to receive between $US35 million and $US45 million in fees.

Barclays and Greenhill, which are advising Teva, should earn somewhere between $US30 million to $US40 million for the deal, Freeman estimated. That doesn’t include all the potential fees to come depending on the size and structure of the equity and debt package.

NOW WATCH: People were shocked to see what this female executive was really like

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at